Buy tech sell-off, Wedbush’s Ives says: ’this is a 1996 moment, not 1999’
DUBLIN - Investment firm Citadel Group has disclosed a 1.56% stake in Mural Oncology plc, according to a regulatory filing published Tuesday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds 271,632 shares representing 1.56% of Mural Oncology’s common stock as of September 29. This includes 258,232 owned or controlled shares and 13,400 shares through stock-settled derivatives.
The filing also reveals Citadel maintains short positions equivalent to 1.11% of the company, primarily through stock-settled derivatives including options.
The disclosure details several transactions conducted on September 29, including multiple purchases of Mural Oncology shares at prices ranging from $2.08 to $2.09 per share. Citadel also reported selling shares during the same period at similar price points.
Additionally, the filing shows Citadel’s options positions, including purchased put options expiring in December 2025 and January 2027, as well as call options with various strike prices ranging from $2.50 to $7.50 with expiration dates extending to March 2026.
Mural Oncology, an Irish-based pharmaceutical company, trades under the ISIN code IE000LK2BOB4. The stock has a par value of $0.01 per ordinary share.
The disclosure was made in compliance with Rule 8.3 of the Irish Takeover Panel Act, which requires public disclosure of interests representing 1% or more in companies that may be involved in takeover situations.
The information was provided in a regulatory news service filing to the London Stock Exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.